MarginsXMarginsX
Home › Markets › Health Care › PBM

Psyence Biomedical Ltd. Common Shares (PBM)

PBM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.83
-11.56% on the day
Market cap
$15.0M
Nano cap
Revenue
Foreign filer: no machine-readable annual figure in SEC data
Net income
Foreign filer: no machine-readable annual figure in SEC data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerPBM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001985062
SEC industry codePharmaceutical Preparations
Incorporated inON

Financials

Foreign filer: no machine-readable annual figure in SEC data.

Warning signs

Cash runway
11.0 months
$7.4M cash at March 31, 2026
Share count, 1 year
+15670.7%
2025-03-31 to 2026-03-31
Going-concern doubt
No
20-F filed June 22, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-06-22
Cash and burn$7.4M cash; operating cash flow -$2.0M a quarter.Report 2026-03-31
Shares outstandingNo cover-page share count in XBRLCover page 2026-03-31
Reverse splits, 3 years4; latest 1-for-6.25 on 2026-02-02Source 2026-02-02
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-08-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorMNP LLP, Toronto, CanadaPCAOB Form AP 2026-06-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2026
2026-03-31
Not filed-$6.9M-$8.1M$7.4M$251KNeeds four quarters20-F 2026-06-22
FY 2025
2025-03-31
Not filed$1.0M-$3.7M$6.1MNo debt tagsNeeds four quarters20-F 2025-06-25
FY 2024
2024-03-31
Not filed-$51.2M-$2.9M$733K$10.4MNeeds four quarters20-F 2025-06-25
FY 2023
2023-03-31
Not filed-$3.2M-$1.6M$1.3MNo debt tagsNeeds four quarters20-F 2025-06-25

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
REGISTRATION STATEMENT
F-32026-08-26
Latest annual report
ANNUAL REPORT
20-F2026-06-22
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-10-21

Source: SEC EDGAR submissions feed, 170 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+6.3%
1 month-30.9%
3 months-11.7%
Year to date-89.3%
1 year-97.1%
From 52-week high-97.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Other listings for this company

TickerNamePrice
PBMWWPsyence Biomedical Ltd. Warrant$0.0121

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BOLTBolt Biotherapeutics Inc.$5.80-4.61%$15.1M
AKTXAkari Therapeutics plc ADS$6.51-4.26%$15.1M
CNTXContext Therapeutics Inc.$0.1659-8.24%$15.2M
ACTUActuate Therapeutics Inc.$0.2680-7.59%$14.7M
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M
CTXRCitius Pharmaceuticals Inc.$0.5276-1.40%$14.5M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M
NCELNewcelX Ltd.$2.75+5.36%$15.9M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier